Among the targets, BDNF, BCL2, BAX, ATF2, APP, TNF, APOE, TGFB1, AKT1, SOD1, AChE, ACE, PPARG (PPAR-γ), PIK3CA, ABCA1, NFKB1, NFE2L2 (Nrf2), MMP9, MAPK1, IL6, IL1B, HMOX1, GRIN2A (GluN2A), CAT, CASP3, and CASP9, each was connected with NDD, indicating the involvement of these targets or others to their upstream signaling as a potential drug-target for fucosterol in the NDD treatment. This evidence concerns the gene BCL2 and Neurodevelopmental delay.